Literature DB >> 23316049

Enhanced membrane-tethered mucin 3 (MUC3) expression by a tetrameric branched peptide with a conserved TFLK motif inhibits bacteria adherence.

Qiong Pan1, Yin Tian, Xiaohuan Li, Jun Ye, Yun Liu, Lili Song, Yongtao Yang, Rong Zhu, Yonghong He, Lei Chen, Wensheng Chen, Xuhu Mao, Zhihong Peng, Rongquan Wang.   

Abstract

We investigated whether a synthetic tetrameric branched peptide based on the conserved TFLK motif from mammary-associated serum amyloid A3 (M-SAA3) is more efficient than the monomeric peptide at up-regulating MUC3 expression and examined the possible mechanism(s) and biological significance of this process. We used standard solid-phase methods to synthesize a tetrameric branched peptide (sequence GWLTFLKAAG) containing a trilysine core, termed the TFLK-containing 10-mer BP. The aberrant expression of transcription factors was analyzed using a transcription factor protein/DNA array. MUC3 and relevant transcription factors were detected using real-time PCR and/or Western blots. The luciferase assay, EMSA, and ChIP assays were used to analyze the activity of the human MUC3 promoter. The bacterial adherence assay was used to evaluate the in vitro inhibition of enteropathogenic Escherichia coli or enterohemorrhage E. coli serotype O157:H7 (EHEC O157:H7) adherence to HT-29-Gal cells after treatment with the TFLK-containing 10-mer BP. In HT-29-Gal cells, the TFLK-containing 10-mer BP induced higher levels of MUC3 expression than the M-SAA3-derived N-terminal 10-mer monomeric peptide, and MUC3 expression was activated through transcriptional mechanisms, including the induction of multiple transcription factors and further binding with their cis-elements between nucleotides -242 and -62 within MUC3 promoter. Interestingly, the TFLK-containing 10-mer BP dramatically inhibited enteropathogenic E. coli and EHEC O157:H7 adherence to the HT-29-Gal cells compared with the controls. This finding suggests a potential therapeutic use for this peptide to prevent gastrointestinal infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316049      PMCID: PMC3581376          DOI: 10.1074/jbc.M112.408245

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The conserved TFLK motif of mammary-associated serum amyloid A3 is responsible for up-regulation of intestinal MUC3 mucin expression in vitro.

Authors:  David R Mack; Thomas L McDonald; Marilynn A Larson; Shu Wei; Annika Weber
Journal:  Pediatr Res       Date:  2003-01       Impact factor: 3.756

2.  Characterization of the mouse Muc3 membrane bound intestinal mucin 5' coding and promoter regions: regulation by inflammatory cytokines.

Authors:  Laurie L Shekels; Samuel B Ho
Journal:  Biochim Biophys Acta       Date:  2003-06-19

3.  Early enterocytic differentiation of HT-29 cells: biochemical changes and strength increases of adherens junctions.

Authors:  S Gout; C Marie; M Lainé; G Tavernier; M R Block; M Jacquier-Sarlin
Journal:  Exp Cell Res       Date:  2004-10-01       Impact factor: 3.905

Review 4.  Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders.

Authors:  R J Playford; C E Macdonald; W S Johnson
Journal:  Am J Clin Nutr       Date:  2000-07       Impact factor: 7.045

Review 5.  Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.

Authors:  R L Guerrant; J M Hughes; N L Lima; J Crane
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

6.  Identification of upstream stimulatory factor as an activator of the human dipeptidyl peptidase IV gene in Caco-2 cells.

Authors:  R H Erickson; R S Lai; C D Lotterman; Y S Kim
Journal:  Gene       Date:  2000-11-27       Impact factor: 3.688

7.  Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro.

Authors:  D R Mack; S Ahrne; L Hyde; S Wei; M A Hollingsworth
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Alteration in expression of MUC2 and MUC3 mRNA levels in HT29 colonic carcinoma cells.

Authors:  D R Mack; M A Hollingsworth
Journal:  Biochem Biophys Res Commun       Date:  1994-03-15       Impact factor: 3.575

9.  Initiation of transcription of the MUC3A human intestinal mucin from a TATA-less promoter and comparison with the MUC3B amino terminus.

Authors:  James R Gum; James W Hicks; Suzanne C Crawley; Christine M Dahl; Stacey C Yang; Anthony M Roberton; Young S Kim
Journal:  J Biol Chem       Date:  2003-09-04       Impact factor: 5.157

10.  Human serum amyloid A3 peptide enhances intestinal MUC3 expression and inhibits EPEC adherence.

Authors:  Marilynn A Larson; Shu H Wei; Annika Weber; David R Mack; Thomas L McDonald
Journal:  Biochem Biophys Res Commun       Date:  2003-01-10       Impact factor: 3.575

View more
  9 in total

Review 1.  Recent advances in adherence and invasion of pathogenic Escherichia coli.

Authors:  Anjana Kalita; Jia Hu; Alfredo G Torres
Journal:  Curr Opin Infect Dis       Date:  2014-10       Impact factor: 4.915

2.  MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells.

Authors:  Yin Tian; Qiong Pan; Yangyang Shang; Rong Zhu; Jun Ye; Yun Liu; Xiaoli Zhong; Shanshan Li; Yonghong He; Lei Chen; Jingjing Zhao; Wensheng Chen; Zhihong Peng; Rongquan Wang
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

3.  Core 2 Mucin-Type O-Glycan Is Related to EPEC and EHEC O157:H7 Adherence to Human Colon Carcinoma HT-29 Epithelial Cells.

Authors:  Jun Ye; Lili Song; Yun Liu; Qiong Pan; Xiaoli Zhong; Shanshan Li; Yangyang Shang; Yin Tian; Yonghong He; Lei Chen; Wensheng Chen; Zhihong Peng; Rongquan Wang
Journal:  Dig Dis Sci       Date:  2015-02-21       Impact factor: 3.199

4.  Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.

Authors:  J Ye; X Wei; Y Shang; Q Pan; M Yang; Y Tian; Y He; Z Peng; L Chen; W Chen; R Wang
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

5.  Single haplotype assembly of the human genome from a hydatidiform mole.

Authors:  Karyn Meltz Steinberg; Valerie A Schneider; Tina A Graves-Lindsay; Robert S Fulton; Richa Agarwala; John Huddleston; Sergey A Shiryev; Aleksandr Morgulis; Urvashi Surti; Wesley C Warren; Deanna M Church; Evan E Eichler; Richard K Wilson
Journal:  Genome Res       Date:  2014-11-04       Impact factor: 9.043

6.  A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor.

Authors:  Hiroaki Shibahara; Michiyo Higashi; Seiya Yokoyama; Karine Rousseau; Iwao Kitazono; Masahiko Osako; Hiroshi Shirahama; Yukie Tashiro; Yasuhiro Kurumiya; Michihiko Narita; Shingo Kuze; Hiroshi Hasagawa; Takehito Kato; Hitoshi Kubota; Hideaki Suzuki; Toshiyuki Arai; Yu Sakai; Norihiro Yuasa; Masahiko Fujino; Shinji Kondo; Yoshichika Okamoto; Tatsuyoshi Yamamoto; Takashi Hiromatsu; Eiji Sasaki; Kazuhisa Shirai; Satoru Kawai; Koutarou Hattori; Hideki Tsuji; Osamu Okochi; Masaki Sakamoto; Akinobu Kondo; Naomi Konishi; Surinder K Batra; Suguru Yonezawa
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

7.  Core 2 mucin-type O-glycan inhibits EPEC or EHEC O157:H7 invasion into HT-29 epithelial cells.

Authors:  Jun Ye; Qiong Pan; Yangyang Shang; Xiaolong Wei; Zhihong Peng; Wensheng Chen; Lei Chen; Rongquan Wang
Journal:  Gut Pathog       Date:  2015-12-15       Impact factor: 4.181

8.  A Selected Lactobacillus rhamnosus Strain Promotes EGFR-Independent Akt Activation in an Enterotoxigenic Escherichia coli K88-Infected IPEC-J2 Cell Model.

Authors:  Wei Zhang; Yao-Hong Zhu; Jin-Cai Yang; Gui-Yan Yang; Dong Zhou; Jiu-Feng Wang
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

9.  Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.

Authors:  Tian Niu; Yidong Liu; Yuan Zhang; Qiang Fu; Zheng Liu; Zewei Wang; Hangcheng Fu; Jiejie Xu; Kun Liu
Journal:  Oncotarget       Date:  2016-08-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.